How many 6-K filings has Biontech Se filed?

Biontech Se (BNTX) has 50 6-K (Foreign Current Report) filings on record, spanning Jun 2024 to Apr 2026.

What is a 6-K filing?

A 6-K is an SEC filing known as "Foreign Current Report." Current report filed by foreign private issuers for material events. Equivalent to the 8-K for domestic companies.

Where can I read Biontech Se 6-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Biontech Se 6-K filings, including risk assessment, sentiment analysis, and key financial figures.

Biontech Se (BNTX) — 6-K Filings

All 6-K filings from Biontech Se. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

BioNTech SE Files 6-K Report — Apr 13, 2026 Risk: low
BioNTech SE filed a Form 6-K on April 13, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form itself and a
BioNTech Completes CureVac Share Exchange Offer — Dec 18, 2025 Risk: medium
On December 18, 2025, BioNTech SE announced the expiration of the subsequent offering period and the successful completion of its exchange offer for all outstan
6-K Filing — Dec 9, 2025
BioNTech SE Files Form 6-K for December 2025 — Dec 8, 2025 Risk: low
On December 6, 2025, BioNTech SE and OncoC4, Inc. presented data from their non-pivotal study. The filing is a Form 6-K, indicating it's a report of a foreign p
6-K Filing — Dec 3, 2025
6-K Filing — Nov 26, 2025
BioNTech SE Hosts Innovation Series R&D Day — Nov 12, 2025 Risk: low
On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, presenting an overview of its research and development pipeline. The company, headquarte
BioNTech SE Reports Q3 2025 Results — Nov 3, 2025 Risk: low
BioNTech SE announced its third quarter 2025 financial results and corporate update on November 3, 2025. The company is a German biotechnology firm headquartere
BioNTech Launches Exchange Offer for CureVac Shares — Oct 22, 2025 Risk: medium
On October 22, 2025, BioNTech SE announced the commencement of an exchange offer for all outstanding shares of CureVac N.V. This filing is a Form 6-K report sub
BioNTech Hosts Second AI Day with InstaDeep — Oct 1, 2025 Risk: low
On October 1, 2025, BioNTech SE, in collaboration with its AI subsidiary InstaDeep Ltd., held its second AI Day. This event showcased advancements and future di
BioNTech SE Enters Global Co-Development Deal — Sep 8, 2025 Risk: medium
On June 2, 2025, BioNTech SE entered into a Global Co-Development and Commercialization Agreement with an unnamed partner. This agreement outlines the terms for
BioNTech SE Files Form 6-K for September 2025 — Sep 5, 2025 Risk: low
On September 5, 2025, BioNTech SE announced a collaboration with Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") regarding a pivotal Phase 3 trial, identifi
BioNTech/Pfizer COVID Vaccine Approved for Young Children — Aug 27, 2025 Risk: low
On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved their supplemental Biologics License Applica
BioNTech SE Reports Ongoing Disputes with CureVac N.V. — Aug 11, 2025 Risk: medium
BioNTech SE filed a Form 6-K on August 11, 2025, reporting ongoing disputes with CureVac N.V. and CureVac SE. The filing indicates that BioNTech and its subsidi
BioNTech SE Reports Q2 2025 Financial Results — Aug 4, 2025 Risk: low
On August 4, 2025, BioNTech SE announced its second quarter 2025 financial results and provided a corporate update. The company is a German biotechnology firm f
BioNTech/Pfizer Vaccine Gets EMA Nod for 2025-26 Season — Jul 25, 2025 Risk: low
On July 25, 2025, BioNTech SE and Pfizer Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended t
BioNTech SE Announces CSO Ryan Richardson's Departure — Jul 17, 2025 Risk: low
On July 17, 2025, BioNTech SE announced that Ryan Richardson will be stepping down from his role as Chief Strategy Officer. The company filed a Form 6-K to repo
BioNTech SE Files 6-K with Purchase Agreement Details — Jun 17, 2025 Risk: low
On June 12, 2025, BioNTech SE entered into a Purchase Agreement, the details of which are included as part of this Form 6-K filing. The company is a European st
BioNTech SE Files Updated Articles of Association — Jun 17, 2025 Risk: low
BioNTech SE filed a Form 6-K on June 17, 2025, to report an English translation of its current Articles of Association. These updated articles were registered w
BioNTech SE Enters Purchase Agreement with CureVac N.V. — Jun 12, 2025 Risk: low
On June 12, 2025, BioNTech SE announced a Purchase Agreement with CureVac N.V., also dated June 12, 2025. This agreement was detailed in a joint press release i
BioNTech SE Announces Collaboration with Bristol Myers Squibb — Jun 2, 2025 Risk: low
On June 2, 2025, BioNTech SE (BNTX) and Bristol Myers Squibb (BMY) announced a collaboration. The specific details of this collaboration, including any financia
BioNTech SE to Present Pipeline Clinical Trial Data — May 27, 2025 Risk: low
On May 27, 2025, BioNTech SE announced it will present clinical trial data from its pipeline candidates at an upcoming event. The company, headquartered in Main
BioNTech Secures UK Government Grant for R&D Expansion — May 20, 2025 Risk: low
On May 20, 2025, BioNTech SE announced that its subsidiary, BioNTech UK Ltd., has entered into a grant agreement with the UK Government. This agreement aims to
BioNTech SE Holds 2025 Annual General Meeting — May 16, 2025 Risk: low
On May 16, 2025, BioNTech SE held its Annual General Meeting (AGM) 2025. The company attached the AGM presentation as Exhibit 99.1 and also provided the voting
BioNTech Appoints New CFO — May 5, 2025 Risk: low
On May 5, 2025, BioNTech SE announced the appointment of Ramó n Zapata-Gomez to its Management Board as Chief Financial Officer, effective immediately. This app
BioNTech to Present Oncology Pipeline Data at AACR Meeting — Apr 24, 2025 Risk: low
On April 24, 2025, BioNTech SE announced its upcoming presentation of data for several oncology pipeline assets, including mRNA cancer immunotherapies. The comp
BioNTech SE Announces 2025 Annual General Meeting Date — Apr 4, 2025 Risk: low
BioNTech SE announced on April 4, 2025, that its Annual General Meeting (AGM) for 2025 will be held on May 16, 2025. The company published the invitation to thi
BioNTech SE Files Form 6-K with SEC — Apr 2, 2025 Risk: low
BioNTech SE announced on April 2, 2025, that it entered into a binding term sheet on December 23, 2024. The filing is a Form 6-K, which is a report of a foreign
BioNTech's BNT141 Vaccine Candidate Faces FDA Clinical Hold — Mar 4, 2025 Risk: medium
On March 4, 2025, BioNTech SE was informed by the U.S. Food and Drug Administration (FDA) that it has placed a clinical hold on BioNTech's investigational new d
BioNTech Acquires Biotheus to Boost Oncology Pipeline — Feb 3, 2025 Risk: low
On February 3, 2025, BioNTech SE announced the successful acquisition of Biotheus, a clinical-stage biotechnology company focused on developing novel antibody-b
BioNTech Outlines 2025 Strategy at J.P. Morgan Conference — Jan 14, 2025 Risk: low
On January 14, 2025, BioNTech SE presented its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The company, headquartered in Mai
BioNTech SE Files 6-K, Discusses NIH Talks — Dec 27, 2024 Risk: low
BioNTech SE filed a Form 6-K on December 27, 2024, reporting its activities for the month of December 2024. The filing indicates that the company is in discussi
BioNTech Partner's Drug IND Application Placed on Clinical Hold — Dec 13, 2024 Risk: medium
BioNTech SE announced on December 13, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investi
BioNTech Hosts Innovation Series Day — Nov 14, 2024 Risk: low
On November 14, 2024, BioNTech SE is holding its Innovation Series Day, presenting updates on its pipeline and strategic initiatives. The details of this event
BioNTech to Acquire Clinical-Stage Biopharma Biotheus — Nov 13, 2024 Risk: medium
On November 13, 2024, BioNTech SE announced the signing of a definitive agreement to acquire Biotheus, a clinical-stage biopharmaceutical company. This acquisit
BioNTech SE Reports Q3 2024 Financial Results — Nov 4, 2024 Risk: low
BioNTech SE announced its third quarter 2024 financial results on November 4, 2024. The company, headquartered in Mainz, Germany, is a foreign private issuer fi
BioNTech Partner's Drug Candidate Faces FDA Clinical Hold — Oct 18, 2024 Risk: medium
BioNTech SE announced on October 18, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investig
BioNTech Showcases AI Progress at AI Day — Oct 1, 2024 Risk: low
On October 1, 2024, BioNTech SE announced its participation in the AI Day presentation, highlighting its advancements in artificial intelligence through its sub
BioNTech/Pfizer COVID Vaccine Gets EU Panel Recommendation — Sep 20, 2024 Risk: low
On September 20, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of their Om
BioNTech to Present Oncology Data at ESMO 2024 — Sep 5, 2024 Risk: low
On September 5, 2024, BioNTech SE announced its intention to present clinical trial data for several oncology pipeline assets. The presentations will occur at t
BioNTech/Pfizer COVID Vaccine Gets FDA Approval for Younger Ages — Aug 22, 2024 Risk: low
On August 22, 2024, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application
BioNTech Cancer Drug Trial Cleared by FDA — Aug 19, 2024 Risk: medium
On August 19, 2024, BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its investigational new drug
BioNTech & Pfizer Announce Phase 3 Vaccine Trial Results — Aug 16, 2024 Risk: low
On August 16, 2024, BioNTech SE and Pfizer Inc. announced top-line results from their Phase 3 clinical trial for a combined vaccine. The filing does not provide
BioNTech SE Updates on Penn Discussions — Aug 7, 2024 Risk: medium
BioNTech SE is providing an update on its ongoing discussions with the University of Pennsylvania (Penn) regarding intellectual property matters. The company pr
BioNTech SE Reports Q2 2024 Financial Results — Aug 5, 2024 Risk: low
On August 5, 2024, BioNTech SE announced its second quarter 2024 financial results. The company is a biopharmaceutical firm focused on infectious diseases, canc
BioNTech SE Announces Positive Phase 2 Data for Influenza Vaccine — Jul 30, 2024 Risk: medium
On July 30, 2024, BioNTech SE announced positive topline data from its Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899). The trial is evaluatin
BioNTech/Pfizer COVID-19 Vaccine Gets EU CHMP Recommendation — Jun 28, 2024 Risk: low
On June 27, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommen
BioNTech's Cancer Drug Gets FDA Fast Track — Jun 24, 2024 Risk: medium
On June 24, 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation
BioNTech cancer vaccine BNT151 gets FDA green light for Phase 1 trial — Jun 17, 2024 Risk: medium
BioNTech SE announced on June 17, 2024, that its partner MediLink Therapeutics (Suzhou) Co., Ltd. has received clearance from the U.S. Food and Drug Administrat
BioNTech SE Presents Promising Phase 2 Data for Kav-cel Combo — Jun 3, 2024 Risk: medium
On June 1, 2024, BioNTech SE announced initial data from its Phase 2 trial for kasvacabtagene autoleucel (kav-cel) in combination with Genmab A/S's epcoritamab

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX